On Thursday, Merck & Co., Inc. (NYSE:MRK)’s shares declined -0.81% to $52.82. The market capitalization of Merck & Co., Inc. (NYSE:MRK) is $147.55 billion with the total traded volume of the company is 8.29 million. Turning to market valuation, the Price-to-Earnings ratio is 14.09, the Price-to-Sales ratio is 3.71 and the Price-to-Book ratio is finally 3.26. The dividend yield amounts to 3.48 percent and the beta ratio has a value of 0.63.
MUFG Americas reduced its position in Merck & Co., Inc. (NYSE:MRK) by 0.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 420,020 shares of the company’s stock after selling 1,063 shares during the period. MUFG Americas’ holdings in Merck & Co. were worth $20,752,000 at the end of the most recent quarter.
Merck & Co., Inc. provides health care solutions worldwide. The company offer therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, male pattern hair loss, and fertility diseases.
Boston Scientific Corporation (NYSE:BSX)’s shares dropped -0.91% to $18.44. The last trading range of Boston Scientific Corporation (NYSE:BSX) ranges between $18.44 and $18.66. The EPS of the company stands at $-0.30. The 52-week range shows that the stock reached higher at $19.06 while its lower range is $13.14 in the last 52-weeks. The average volume of the company is at 7.79 million with the Outstanding Shares of 1.35 billion. The market capitalization of the company is $24.81 billion. The Beta of the company stands at 1.04 with the RSI (Relative Strength Index) of 47.41.
Boston Scientific Corporation (NYSE:BSX) has lost 1.5% during the past week and dropped 0.38% in the last 4 weeks. The shares have underperformed the S&P 500 by 0.67% during the past week but Boston Scientific Corporation (NYSE:BSX) has outperformed the index in 4 weeks by 1.95%.
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in three segments: Cardiovascular, Rhythm Management, and MedSurg. It offers interventional cardiology products, including coronary stent systems used in the treatment of coronary artery disease; coronary technology products to treat atherosclerosis; intraluminal catheter-directed ultrasound imaging catheters and systems for use in coronary arteries and heart chambers, as well as peripheral vessels; and structural heart therapy systems.
Oclaro, Inc. (NASDAQ:OCLR)‘s shares dipped -4.13% to $3.48. Oclaro, Inc. (NASDAQ:OCLR) is now worth about $385.43 million. The share price has made a -2.79% loss in the past 5 days and has lost -4.13% since 2015 kicked off. Analysts are forecasting EPS growth of -0.29% for next fiscal year and 10.00% growth in the next 5 years. The stock trades with a beta of 2.62. The stock price is above by 35.88% as contrast to the average price over the last 200 days. The company has 19.20% gross margins.
Oclaro, Inc. designs, manufactures, and markets lasers and optical components, modules, and subsystems for the optical communications, industrial, and consumer laser markets worldwide. The company’s products generate, detect, combine, and separate light signals in optical communications networks.
